UK teenagers could get a routine MenB dose at 15

beehiveweb.co.uk editorial team 2026-07-21 12:37 4 min read

An illuminated medical clinic sign glowing at night against a dark background

By Beehive Web Health Desk | 21 July 2026

A routine MenB vaccination could be offered to teenagers at around age 15 under new advice submitted to the UK Government, but the NHS schedule has not yet changed.

The Joint Committee on Vaccination and Immunisation (JCVI) issued its recommendation after reviewing new evidence and the MenB outbreak in Kent earlier in 2026. The Department of Health and Social Care must now consider the advice before deciding whether to introduce any additional vaccination offer.

Proposed dose would begin with teenagers born from May 2015

The JCVI recommends one dose of the 4CMenB vaccine at around age 15 for adolescents who were eligible for MenB vaccination during infancy. This group, described as “primed adolescents”, includes those born on or after 1 May 2015.

The first teenagers covered by that recommendation will turn 15 in 2030. It is therefore a proposal for a future routine programme, rather than a vaccination being added immediately to the current adolescent schedule.

UK teenagers could get a routine MenB dose at 15

The committee also strongly supports offering two doses to “unprimed adolescents” born on or before 30 April 2015 at around the same age. It wants a catch-up programme for adolescents who would fall between the existing one-off 2026 offer and the proposed age-15 programmes.

JCVI acknowledged uncertainty over the cost-effectiveness of these additional groups. It nevertheless described vaccination as highly important on equity grounds because a catch-up offer could bridge the gap until the routine programme for primed adolescents begins.

Kent outbreak prompted a fresh review

The advice follows what the UK Health Security Agency described as an unprecedented MenB outbreak in Kent this year. That outbreak led the Health and Social Care Secretary to ask the JCVI to reconsider routine adolescent vaccination.

Invasive meningococcal disease is rare but can be extremely serious and cause life-changing complications or death. The committee said it considered testimony gathered with meningitis charities, including accounts submitted for people who died or experienced lasting complications.

The outbreak is the reason for the review, but the JCVI recommendation concerns a possible nationwide programme rather than a Kent-only schedule.

New evidence supports an additional adolescent dose

The JCVI examined recent evidence concerning the effectiveness of an additional single dose in adolescents who had received MenB vaccination as babies. The 4CMenB vaccine has formed part of the childhood vaccination programme since 2015.

According to the committee, infant vaccination is highly effective and provides strong protection lasting for at least five years. The proposed adolescent dose is intended to extend individual protection into another period when the risk of this rare disease may be higher.

Experts also considered how long protection lasts after two doses, current and possible future levels of invasive meningococcal disease, recent outbreaks and cost-effectiveness modelling. Possible protection against gonococcal infection was reviewed as part of the evidence, but the published recommendation remains focused on MenB vaccination.

The current NHS offers have not been replaced

Children who are eligible continue to receive 4CMenB through the childhood vaccination programme. The proposed routine dose at age 15 is additional to that programme and cannot be treated as available until the Government reaches a decision.

A separate, time-limited MenB offer is already operating in 2026 for eligible young people. It includes some people starting an undergraduate university course or moving into residential further education for the first time this autumn.

That one-off programme requires two MenB doses given at least 28 days apart. Professor Wei Shen Lim, chair of the JCVI, urged eligible young people to book through the online service for vaccination at a local pharmacy in time to receive their second dose before leaving for university or college.

Government consideration is the next decision point

The Department of Health and Social Care has not announced whether it will accept the JCVI recommendation or when a final decision will be made. Until that happens, families should distinguish the proposed routine adolescent programme from the one-off vaccination currently available.

Parents and teenagers should check eligibility for the 2026 offer through official NHS or UK Health Security Agency information rather than assume that every adolescent can book now. Those who qualify need two doses at least 28 days apart; the proposed single routine dose for primed 15-year-olds would not begin with its first cohort until 2030.

Source: UK Health Security Agency News

Context & actions About this article

Source check Source trail

This report distinguishes the JCVI recommendation from the vaccination offers currently available through the NHS.

Checks

Confirmed that the JCVI advice is not a final change to the NHS vaccination schedule.
Checked the proposed age, dose and birth-date criteria for primed and unprimed adolescents...
Separated the future routine proposal from the time-limited two-dose offer operating in 20...
Retained the stated uncertainty concerning the cost-effectiveness of catch-up vaccination.

UK Health Security Agency Check wider reporting